Certara Logo White Background.png
Certara Announces New Versions of Biosimulation Software for Development of Novel Biologics
June 21, 2022 08:00 ET | Certara
PRINCETON, N.J., June 21, 2022 (GLOBE NEWSWIRE) -- Certara Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the release of new versions of its Immunogenicity (IG),...
7 Hills Logo.png
7 Hills Pharma Expands Pioneering Patent Portfolio With New Claims Covering Innovative Combination Therapies
June 09, 2022 19:53 ET | 7 Hills Pharma
HOUSTON, June 09, 2022 (GLOBE NEWSWIRE) -- 7 Hills Pharma LLC (“7 Hills” or “7HP”) has secured newly issued US patent claims that significantly expand the extent of the company’s intellectual...
arvinas_logoART_lg.jpg
Arvinas to Present at Goldman Sachs 43rd Annual Global Healthcare Conference
June 02, 2022 16:00 ET | Arvinas Inc.
NEW HAVEN, Conn., June 02, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
arvinas_logoART_lg.jpg
Arvinas Launches Global Early Career Researcher Award and Announces Call for Nominations
June 01, 2022 08:00 ET | Arvinas Inc.
-- In honor of 20 years of targeted protein degradation, Arvinas announces $25,000 prize to recognize the efforts of an up-and-coming researcher in the field of targeted protein degradation – --...
Compass-logo-RGB-outlines.png
Compass Therapeutics to Present at the 2022 Jefferies Global Healthcare Conference
May 31, 2022 08:00 ET | Compass Therapeutics
BOSTON, May 31, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer,...
Compass-logo-RGB-outlines.png
Compass Therapeutics to Present at the 2022 H.C. Wainwright Annual Global Investment Conference
May 23, 2022 08:00 ET | Compass Therapeutics
BOSTON, May 23, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer,...
7 Hills Logo.png
New Study Demonstrates Integrin Activation Can Bring the Heat to Cold Melanoma Tumors
May 18, 2022 19:23 ET | 7 Hills Pharma
HOUSTON, May 18, 2022 (GLOBE NEWSWIRE) -- 7 Hills Pharma LLC (“7 Hills” or “7HP”), together with The University of Texas MD Anderson Cancer Center (“MD Anderson”) and Texas Heart Institute (“THI”),...
IDERA_5C_RGB-01.jpg
Idera Pharmaceuticals Shares Positive Results from Investigator-Sponsored Trial in Melanoma Patients at Amsterdam UMC
May 17, 2022 08:04 ET | Idera Pharmaceuticals, Inc.
EXTON, Pa., May 17, 2022 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera,” “we,” and “our”) (Nasdaq: IDRA) today shared positive interim results from Amsterdam UMC, Vrije Universiteit...
Immunicum AB: Immunicum Announces Positive Interim Results from ADVANCE II Study in AML Maintenance Treatment
May 16, 2022 02:00 ET | Immunicum AB
Analysis of primary study endpoint was completed with 7 patients showing a measurable residual disease (MRD) response, of which 5 patients converted from MRD+ to MRD- and 2 patients showed a...
Immunicum AB: Immunicum tillkännager positiva interimsresultat från ADVANCE II-studie i AML-underhållsbehandling
May 16, 2022 02:00 ET | Immunicum AB
Analys av primärstudiens effektmått slutfördes med 7 patienter som visade ett mätbar restsjukdom (MRD)-svar, varav 5 patienter konverterade från MRD+ till MRD- och 2 patienter som visade en avsevärd,...